Symeres Acquires DGr Pharma

Symeres, a global contract research, development and manufacturing organization (CRDMO), has acquired DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients.

The acquisition is supported by Keensight Capital, a private equity manager dedicated to pan-European Growth Buyout investments.

Founded in 2018 and based in the Netherlands, DGr Pharma specializes in pre-clinical and clinical regulatory strategy and consultancy for biotech and pharmaceutical partners working in early drug development. Its core services include chemical-pharmaceutical, non-clinical and clinical development planning, quality assurance, and regulatory submissions. DGr Pharma has expertise in small and large molecules, including antibodies, ADCs and oligonucleotides. With a reputation for scientific rigor, DGr Pharma adds regulatory depth to the Symeres portfolio, enabling it to deliver a more integrated solution across the full spectrum of drug discovery and development.

DGr Pharma’s pharmacokinetic data analysis services operate under Good Clinical Practice (GCP) and Good Laboratory Practice (GLP), expertise that aligns with Symeres’ integrated offering, including ADME. The GLP status enhances data quality and regulatory readiness, giving Symeres’ clients a more efficient and reliable path to IND submission.

Guillaume Jetten, CEO of Symeres, said: “This acquisition strengthens our ability to offer truly integrated solutions across the drug discovery and development spectrum. DGr Pharma’s expertise enhances our scientific capabilities, allowing us to better support our clients’ evolving needs and reinforce Symeres’ position as a partner of choice in the global biopharma market.”

Kees Groen, Founder and CEO of DGr Pharma, added: “This is an exciting new chapter for DGr Pharma. Joining Symeres provides us with the opportunity to grow our reach and expand the value we bring to clients, particularly in early-stage development. We share Symeres’ commitment to high-quality science, long-term relationships and entrepreneurial ambition and we look forward to being part of the next phase of growth.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.